Pulse Biosciences (NASDAQ:PLSE) Releases Earnings Results, Misses Estimates By $0.07 EPS

Pulse Biosciences (NASDAQ:PLSE) posted its earnings results on Thursday. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07), FiscalAI reports. The business had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $0.53 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 100.22%.

Here are the key takeaways from Pulse Biosciences’ conference call:

• nPulse AF catheter enrollment is ahead of schedule: The pivotal NANOPULSE-AF study surpassed the halfway point with more than 82 evaluable patients, and enrollment is now expected to finish in early October, despite expanding the target from 145 to 164 patients.
• Early clinical and workflow feedback remains highly favorable, with physicians reporting five to seven cases per day and ablation times as short as five to eight minutes. Management believes the resulting throughput and hospital economics could support significant adoption, though pivotal outcomes remain pending.
• European feasibility data for the cardiac catheter showed 96% freedom from AF at one year by 24-hour Holter monitoring, 90% freedom from recurrent AF, flutter, or tachycardia by Kaplan-Meier analysis, and a 1.7% serious adverse event rate across 177 patients. The company remains on track to submit for a CE mark in the second half of 2026 and potentially receive approval around mid-2027.
• Pulse strengthened its balance sheet through $57.5 million of net ATM proceeds, ending Q2 with $101.6 million in cash and extending its runway through key clinical and regulatory milestones. It also established a new $75 million ATM facility and received $1.8 million from warrant exercises.
• Spending and losses increased as the company accelerated clinical and product development, with Q2 GAAP operating expenses rising to $25.7 million and GAAP net loss reaching $24.7 million. Operating cash use rose to $18.7 million, while management expects quarterly non-GAAP expenses to remain near current levels.

Pulse Biosciences Stock Performance

PLSE traded up $4.17 during trading on Friday, hitting $42.41. 734,091 shares of the stock were exchanged, compared to its average volume of 361,024. The firm has a 50 day simple moving average of $29.01 and a 200 day simple moving average of $23.64. The firm has a market cap of $2.94 billion, a price-to-earnings ratio of -35.94 and a beta of 1.61. Pulse Biosciences has a 1 year low of $12.56 and a 1 year high of $45.90.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Canaccord Genuity Group initiated coverage on Pulse Biosciences in a research note on Thursday, June 4th. They issued a “buy” rating and a $32.00 price objective for the company. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Wall Street Zen downgraded Pulse Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.33.

Insider Buying and Selling at Pulse Biosciences

In other news, Director Robert W. Duggan purchased 660,233 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $19.69 per share, with a total value of $12,999,987.77. Following the transaction, the director owned 48,211,433 shares of the company’s stock, valued at $949,283,115.77. This represents a 1.39% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Paul A. Laviolette purchased 15,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $19.69 per share, for a total transaction of $295,350.00. Following the purchase, the chief executive officer owned 15,000 shares of the company’s stock, valued at approximately $295,350. This trade represents a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 74.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Pulse Biosciences

Hedge funds have recently modified their holdings of the business. Bank of America Corp DE lifted its holdings in Pulse Biosciences by 2.7% during the third quarter. Bank of America Corp DE now owns 804,960 shares of the company’s stock worth $14,248,000 after buying an additional 21,424 shares during the period. State Street Corp grew its position in shares of Pulse Biosciences by 6.0% in the 4th quarter. State Street Corp now owns 447,067 shares of the company’s stock worth $6,138,000 after buying an additional 25,187 shares during the last quarter. Brooklyn Investment Group raised its stake in shares of Pulse Biosciences by 330.7% during the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock worth $1,844,000 after acquiring an additional 100,081 shares in the last quarter. Portolan Capital Management LLC purchased a new stake in Pulse Biosciences during the third quarter valued at approximately $1,809,000. Finally, UBS Group AG lifted its position in Pulse Biosciences by 53.4% during the third quarter. UBS Group AG now owns 76,856 shares of the company’s stock valued at $1,360,000 after acquiring an additional 26,739 shares during the last quarter. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.